CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

The Morel Company

A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.

Summit Counseling Solutions

Summit Counseling Solutions is a mental health care provider that offers adolescent day treatment and intensive outpatient services.

Biomed International

Biomed International is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biocodex

Biocodex is a San Bruno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.